drugset / Trial / NCT04713891
A Study of KF-0210 in Advanced Solid Tumors Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors. The study will be conducted in two parts: phase Ia, and phase Ib.
Timeline
- Start
- 2021-03-09
- Primary completion
- 2022-12-08
- Completion
- 2023-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | KF-0210 | Unknown | 120 mg | Oral |
| Subject | KF-0210 | Unknown | 240 mg | Oral |
| Subject | KF-0210 | Unknown | 450 mg | Oral |
| Subject | KF-0210 | Unknown | 600 mg | Oral |